The 60,000-plus test unit agreement will support high-throughput STI testing operations with improved detection limits.
Nexus Medical Labs has entered into a partnership with Lybe Scientific to implement the NAxtra nucleic acid extraction kit across its high-throughput sexually transmitted infection (STI) testing operations.
The agreement for more than 60,000 test units represents Nexus’ continued investment in extraction technologies to enhance its diagnostic capabilities. The partnership resulted from Nexus’ research and development team conducting a literature search for new extraction technologies that could support molecular workflows.
“Our R&D team conducted a literature search for new extraction technologies that could support our molecular workflows. A paper published about NAxtra magnetic nanoparticles sparked our initial interest,” says Esther Brown, vice president of operations at Nexus Medical Labs, in a release.
Exceeding Detection Expectations
Following collaboration and adaptation of Lybe Scientific’s products and protocols, the NAxtra nucleic acid extraction kit exceeded performance expectations, according to a company release. The technology delivered measurable improvements in limit of detection across Nexus’ STI testing panels.
“We were expecting to simply match our current limit of detection but were pleasantly surprised to see measurable improvement when using the NAxtra extraction kit across our STI testing panels,” says Brown in a release.
The extraction kit’s workflow simplicity, minimal reagent requirements, and rapid time to result support Nexus’ high-throughput sample processing requirements.
Expanding Market Applications
The NAxtra technology has gained traction beyond healthcare applications, including in the aquaculture industry. The US healthcare sector interest demonstrates the broad applicability of Lybe Scientific’s products across multiple markets.
“Our NAxtra technology suits all laboratories that value high precision and swift diagnostic workflows for biological samples. This deal confirms that our strategic investments in improving the limit of detection were correct and are in line with the actual needs in the market,” says Dr Tonje Steigedal, CEO of Lybe Scientific, in a release.
Steigedal notes that being selected by Nexus Medical Labs validates the value the products bring to modern diagnostic pipelines, particularly given the demanding market requirements for quality, technical capability, and speed.
The collaboration between the companies has been marked by strong communication and technical support. Jill Sullivan, vice president of growth at Nexus, says the partnership has been characterized by excellent communication and technical insight from Lybe Scientific. “To date, our communication with Lybe Scientific has been excellent, and we’ve been consistently impressed by the level of thought and technical insight they’ve offered to help us improve our results,” says Sullivan in a release.
Photo caption: Laboratory image
Photo credit: Lybe Scientific
